Table of contents
From the editors
p453 | doi:10.1038/nrc2692
Research Highlights
Signalling: Hedgehog doesn't... | PDF (243 KB)
p455 | doi:10.1038/nrc2688
Senescence: Playing games with epigenetics | PDF (157 KB)
p456 | doi:10.1038/nrc2685
Angiogenesis: How Down's syndrome protects | PDF (276 KB)
p456 | doi:10.1038/nrc2687
Therapeutics: Dependent on KRAS | PDF (182 KB)
p457 | doi:10.1038/nrc2689
Breast cancer: Prioritizing targets | PDF (146 KB)
p458 | doi:10.1038/nrc2684
Drug resistance: Getting through | PDF (317 KB)
p458 | doi:10.1038/nrc2686
In the news
Canine first | PDF (175 KB)
p458 | doi:10.1038/nrc2691
In brief
Metastasis | Tumorigenesis | Non-coding RNA | Tumour initiation | PDF (122 KB)
p459 | doi:10.1038/nrc2690
Breast cancer: Metastasis on the brain | PDF (161 KB)
p460 | doi:10.1038/nrc2678
Breast cancer: A DEAR 1 | PDF (199 KB)
p460 | doi:10.1038/nrc2680
Epigenetics: Misreading the code | PDF (179 KB)
p461 | doi:10.1038/nrc2679
Reviews
Article series: Therapeutic resistance
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
José Baselga & Sandra M. Swain
p463 | doi:10.1038/nrc2656
Targeting the Erbb family of receptor tyrosine kinases, specifically ERBB1 (EGFR) and ERBB2, has led to successful cancer therapies. However, many patients will progress on these therapies. As we learn more about this pivotal receptor family, can we devise better methods of targeting it?
Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers
Stephen S. Hecht, Fekadu Kassie & Dorothy K. Hatsukami
p476 | doi:10.1038/nrc2674
Chemoprevention of lung carcinogenesis is one potential approach to control the epidemic of lung cancer caused by cigarette smoking. How should we go about this and is using mixtures of chemopreventive agents a useful path to pursue?
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther, Elaine Johnstone, Charles Swanton, Rachel Midgley, Ian Tomlinson & David Kerr
p489 | doi:10.1038/nrc2645
New technologies have led to an explosive increase in the number of biomarkers thought to be associated with prognosis and treatment outcome in colorectal cancer. How effective are the biomarkers already in the public domain?
Perspectives
Timeline
Apoptosis and cancer: the genesis of a research field
Thomas G. Cotter
p501 | doi:10.1038/nrc2663
Ever since its discovery, apoptosis has been inextricably linked with cancer. This Timeline article seeks to provide insights into the key discoveries in the field and therapeutic applications based on apoptotic strategies.
Timeline
Cancer prevention research — then and now
Ann M. Bode & Zigang Dong
p508 | doi:10.1038/nrc2646
Cancer prevention is a global priority, but history indicates that the journey towards achieving this goal is fraught with difficulties. What can we learn from the past that is applicable to the reality of successful cancer prevention?
Science and society
Wildlife cancer: a conservation perspective
Denise McAloose & Alisa L. Newton
p517 | doi:10.1038/nrc2665
Cancer in wildlife seems to be more prevalent than previously thought and could have considerable effects on the populations of some species. This Perspective discusses the conservation issues raised by cancer in wildlife.
See also: Correspondence by Erren et al. | Correspondence by McAloose & Newton
